Genmab A/S (NASDAQ:GMAB) Shares Gap Down – Should You Sell?

Genmab A/S (NASDAQ:GMAB) gapped down prior to trading on Tuesday . The stock had previously closed at $19.58, but opened at $19.09. Genmab A/S shares last traded at $18.95, with a volume of 227,258 shares trading hands.

Analyst Ratings Changes

Several brokerages have recently issued reports on GMAB. Leerink Partners raised Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 target price on the stock in a report on Thursday, February 13th. Truist Financial decreased their price objective on Genmab A/S from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Tuesday, March 11th. HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a research report on Thursday, January 23rd. William Blair upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 11th. Finally, BNP Paribas upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 11th. One analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $41.33.

Genmab A/S Stock Down 2.7 %

The company has a market capitalization of $12.60 billion, a PE ratio of 10.93, a price-to-earnings-growth ratio of 2.65 and a beta of 0.98. The firm’s 50 day simple moving average is $20.87 and its 200 day simple moving average is $21.79.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. As a group, sell-side analysts predict that Genmab A/S will post 1.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. lifted its stake in shares of Genmab A/S by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company’s stock worth $186,000 after acquiring an additional 827 shares during the last quarter. EverSource Wealth Advisors LLC increased its stake in Genmab A/S by 295.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock worth $26,000 after purchasing an additional 939 shares during the period. Lindbrook Capital LLC lifted its position in shares of Genmab A/S by 105.4% during the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock worth $39,000 after purchasing an additional 950 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Genmab A/S by 96.6% during the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after purchasing an additional 1,051 shares during the last quarter. Finally, Grandfield & Dodd LLC boosted its stake in shares of Genmab A/S by 4.2% during the fourth quarter. Grandfield & Dodd LLC now owns 33,733 shares of the company’s stock valued at $704,000 after purchasing an additional 1,370 shares during the period. Hedge funds and other institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.